These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22525224)

  • 1. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma.
    Schuetze SM; Zhao L; Chugh R; Thomas DG; Lucas DR; Metko G; Zalupski MM; Baker LH
    Eur J Cancer; 2012 Jun; 48(9):1347-53. PubMed ID: 22525224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
    Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
    J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.
    Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY
    J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
    Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM
    Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
    Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
    Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas.
    Bernstein-Molho R; Kollender Y; Issakov J; Bickels J; Dadia S; Flusser G; Meller I; Sagi-Eisenberg R; Merimsky O
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):855-60. PubMed ID: 23053256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
    Hobday TJ; Qin R; Reidy-Lagunes D; Moore MJ; Strosberg J; Kaubisch A; Shah M; Kindler HL; Lenz HJ; Chen H; Erlichman C
    J Clin Oncol; 2015 May; 33(14):1551-6. PubMed ID: 25488966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Investigation of Safety and Efficacy of Nivolumab and
    Gordon EM; Angel NL; Omelchenko N; Chua-Alcala VS; Moradkhani A; Quon D; Wong S
    Anticancer Res; 2023 May; 43(5):1993-2002. PubMed ID: 37097693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
    Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
    Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
    Martin-Liberal J; Gil-Martín M; Sáinz-Jaspeado M; Gonzalo N; Rigo R; Colom H; Muñoz C; Tirado OM; García del Muro X
    Br J Cancer; 2014 Aug; 111(5):858-65. PubMed ID: 25003665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
    Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
    Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
    Sehdev A; Karrison T; Zha Y; Janisch L; Turcich M; Cohen EEW; Maitland M; Polite BN; Gajewski TF; Salgia R; Pinto N; Bissonnette MB; Fleming GF; Ratain MJ; Sharma MR
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):309-317. PubMed ID: 29948021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
    Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination.
    Carr RM; Duma N; McCleary-Wheeler AL; Almada LL; Marks DL; Graham RP; Smyrk TC; Lowe V; Borad MJ; Kim G; Johnson GB; Allred JB; Yin J; Lim VS; Bekaii-Saab T; Ma WW; Erlichman C; Adjei AA; Fernandez-Zapico ME
    Pancreatology; 2020 Sep; 20(6):1115-1122. PubMed ID: 32778368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.